ArticleAntibiotics (Basel, Switzerland)2020
Simultaneous Control of
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Isolation and characterization of Avs-1, a bacteriophage effective against the aquaculture pathogenApplied and environmental microbiology · 2026Article
- Bacteriophage BCP01 and Its Endolysin as Tools for Biocontrol and Rapid Detection ofJournal of microbiology and biotechnology · 2026Article
- Bacteriophages and Endolysins Used in the Biocontrol ofMicroorganisms · 2025Review
- A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections.PHAGE (New Rochelle, N.Y.) · 2024Review
- "Tear down that wall"-a critical evaluation of bioinformatic resources available for lysin researchers.Applied and environmental microbiology · 2024Review
- Isolation and Characterization of a Novel Virulent Phage ASG01 ofMicroorganisms · 2024Article
- Rapid Screening and Comparison of Chimeric Lysins for Antibacterial Activity againstAntibiotics (Basel, Switzerland) · 2023Article
- A comprehensive review of the applications of bacteriophage-derived endolysins for foodborne bacterial pathogens and food safety: recent advances, challenges, and future perspective.Frontiers in microbiology · 2023Review
- Characterization of the Novel Phage vB_VpaP_FE11 and Its Potential Role in ControllingViruses · 2022Article
- Endolysin, a Promising Solution against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2021Review
- Phages and Enzybiotics in Food Biopreservation.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Bacteriophage endolysins have attracted attention as promising alternatives to antibiotics, and their modular structure facilitates endolysin engineering to develop novel endolysins with enhanced versatility. Here, we constructed hybrid proteins consisting of two different endolysins for simultaneous control of two critical foodborne pathogens,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.